TMD in Down Syndrome. Issue 4 (December 2022)

• Record Type: Journal Article
• Authors: Ch., Suguna Reddy; D., Vardhini Sree
• Is Part Of: Journal of neonatology. Volume 36:Issue 4(2022)
• Page Start: 366
• Page End: 370
• Publication Date: 2022-12
• Subjects: Transient abnormal myelopoiesis (TAM) -- transient myeloproliferative disorder (TMD) -- Down syndrome -- GATA-1; Neonatology -- Periodicals; Neonatology -- India -- Periodicals; 618.9201
• DOI: 10.1177/09732179221100655
• Languages: English
• ISSNs: 0973-2179

Abstract

Down syndrome is the most common autosomal trisomy with an incidence of 1 in 700 to 800 live births. 1 Hematologic abnormalities are common in Down syndrome. 10% of infants with Down syndrome develop an abnormal myeloproliferative disorder called transient abnormal myelopoiesis (TAM). 2 It occurs because of uncontrolled proliferation of myeloblasts in peripheral blood and bone marrow and is characterized by the presence of GATA-1 mutation along with trisomy 21. The majority of the cases show spontaneous remission without the need for chemotherapy, and only supportive care is required for such cases. We present a newborn with Down syndrome who developed TAM within the first week of life and showed spontaneous remission with supportive care.